Breast Cancer Clinical Trial

Chemotherapy Induced Peripheral Neuropathy Natural History Study (EPIPHANY)

Summary

This is a prospective natural history study of CIPN in approximately 200 participants receiving taxanes (paclitaxel, docetaxel) for breast cancer, bortezomib for multiple myeloma, oxaliplatin-based regimens for colorectal cancer, or vincristine for lymphoma.. Demographic data, medical history, electronic PROs, ClinROs blood biomarkers including NF-L, PGx DNA analyses and Bedside-QST will be assessed at Baseline. The Observation Period will initiate with the first dose of chemotherapy and conclude with the last dose of chemotherapy. During the Observation Period, participants will be evaluated for the development of CIPN using PROs and ClinROs. Blood biomarkers and Bedside-QST will be measured at various timepoints corresponding with treatment regimen schedules throughout the observation period. The Post Chemotherapy Follow-up Period will begin with the first visit after the last dose of chemotherapy and conclude 6 months after the last dose of chemotherapy. During the Post Chemotherapy Follow-up Period, participants will be evaluated for CIPN using PROs and ClinROs. Blood biomarkers and Bedside-QST will also be measured at the beginning and at the end of the Post-Chemotherapy Follow-up Period. PROs will be assessed electronically on a monthly basis.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

All of the following criteria must be met in order to be enrolled in the study:

Age ≥18 years
Life expectancy ≥6 months
Participants with Common Terminology Criteria for Adverse Events (CTCAE) Grade 0 CIPN (exception, patients with multiple myeloma treated with bortezomib, CTCAE Grade <=1)
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

Breast cancer only:

Breast cancer beginning treatment with paclitaxel or docetaxel with curative intent (i.e., not metastatic disease beyond regional lymph nodes)
Planned minimum of 6 cycles of chemotherapy

Lymphoma only:

Incident lymphoma initiating treatment with vincristine
Planned minimum of 4 cycles of chemotherapy
Oxaliplatin-based regimens, Stage III colorectal cancer: Total of 6 months (planned minimum of 12 cycles). May consider Stage IV with minimal metastatic confirmed with Sponsor prior to enrollment
Bortezomib use in untreated multiple myeloma: Total of 4 months (planned minimum of 9 cycles)
Written informed consent given
Enrollment must be completed prior to receiving the first dose of chemotherapy

Exclusion Criteria:

Patients meeting ANY of the following criteria are not eligible for participation:

Evidence of central nervous system metastases
Evidence of clinically significant peripheral neuropathy (CTCAE >2) as defined by patient report of frequent numbness or tingling in the hands or feet
Any uncontrolled serious illness or medical condition that would impact the conduct of the current study
Previous exposure to neurotoxic chemotherapy drugs
Pre-existing neurodegenerative disease (Parkinson's, Alzheimer's, Huntington's, etc.), neuromuscular disorder (multiple sclerosis, ALS, polio, hereditary neuromuscular disease) or history of stoke or history of traumatic brain injury
General anesthesia less than one month prior to the first dose of neurotoxic chemotherapy

Study is for people with:

Breast Cancer

Estimated Enrollment:

200

Study ID:

NCT03997981

Recruitment Status:

Recruiting

Sponsor:

Disarm Therapeutics

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 12 Locations for this study

See Locations Near You

University of Arizona Cancer Center
Tucson Arizona, 85724, United States More Info
Pavani Chalasani, MD, MPH
Principal Investigator
Marin Cancer Center
Greenbrae California, 94904, United States More Info
Contact
415-925-5000
Kristin Anderson, MD
Principal Investigator
Alpha Oncology Research LLC
Orange City Florida, 32763, United States More Info
Contact
407-353-1915
Santosh Nair, MD
Principal Investigator
University of Maryland
Baltimore Maryland, 21201, United States More Info
Susan Dorsey, Ph.D, RN, FAAN
Principal Investigator
Johns Hopkins University School of Medicine
Baltimore Maryland, 21287, United States More Info
Contact
410-955-8893
N Wagner- Johnston
Principal Investigator
University of Michigan
Ann Arbor Michigan, 48109, United States
Washington University
Saint Louis Missouri, 63110, United States More Info
Simon Haroutounian, Ph.D, MSc
Principal Investigator
Mayo Clinic
Rochester New York, 55905, United States More Info
Nathan Staff, MD, Ph.D
Principal Investigator
OSU- James Comprehensive Cancer Center
Columbus Ohio, 43212, United States More Info
Maryam Lustberg, MD, MPH
Principal Investigator
University of Pensylvania
Philadelphia Pennsylvania, 19104, United States More Info
Chafic Karam
Principal Investigator
University of Vermont Medical Center
Burlington Vermont, 05401, United States More Info
Noah Kolb, MD
Principal Investigator
VCU Medical Center
Richmond Virginia, 23298, United States More Info
Gordon Smith, MD
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Estimated Enrollment:

200

Study ID:

NCT03997981

Recruitment Status:

Recruiting

Sponsor:


Disarm Therapeutics

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.